nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ADRA2A—epilepsy syndrome	0.231	0.723	CbGaD
Dihydroergotamine—ABCB1—epilepsy syndrome	0.0884	0.277	CbGaD
Dihydroergotamine—ABCB1—Levetiracetam—epilepsy syndrome	0.0296	0.0906	CbGbCtD
Dihydroergotamine—ABCB1—Clobazam—epilepsy syndrome	0.0205	0.0628	CbGbCtD
Dihydroergotamine—ABCB1—Lamotrigine—epilepsy syndrome	0.0197	0.0605	CbGbCtD
Dihydroergotamine—ABCB1—Carbamazepine—epilepsy syndrome	0.017	0.0521	CbGbCtD
Dihydroergotamine—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0162	0.0497	CbGbCtD
Dihydroergotamine—ABCB1—Phenytoin—epilepsy syndrome	0.0152	0.0467	CbGbCtD
Dihydroergotamine—CYP3A4—Felbamate—epilepsy syndrome	0.0151	0.0462	CbGbCtD
Dihydroergotamine—CYP3A4—Trimethadione—epilepsy syndrome	0.0151	0.0462	CbGbCtD
Dihydroergotamine—CYP3A4—Fosphenytoin—epilepsy syndrome	0.0142	0.0434	CbGbCtD
Dihydroergotamine—ABCB1—Phenobarbital—epilepsy syndrome	0.0136	0.0416	CbGbCtD
Dihydroergotamine—ABCB1—Midazolam—epilepsy syndrome	0.0134	0.041	CbGbCtD
Dihydroergotamine—ABCB1—Diazepam—epilepsy syndrome	0.0129	0.0394	CbGbCtD
Dihydroergotamine—CYP3A4—Clonazepam—epilepsy syndrome	0.0128	0.0393	CbGbCtD
Dihydroergotamine—CYP3A4—Clobazam—epilepsy syndrome	0.0123	0.0376	CbGbCtD
Dihydroergotamine—HTR1D—meninx—epilepsy syndrome	0.0122	0.223	CbGeAlD
Dihydroergotamine—CYP3A4—Rufinamide—epilepsy syndrome	0.0104	0.032	CbGbCtD
Dihydroergotamine—CYP3A4—Carbamazepine—epilepsy syndrome	0.0102	0.0312	CbGbCtD
Dihydroergotamine—CYP3A4—Primidone—epilepsy syndrome	0.00951	0.0291	CbGbCtD
Dihydroergotamine—CYP3A4—Phenytoin—epilepsy syndrome	0.00913	0.028	CbGbCtD
Dihydroergotamine—CYP3A4—Propofol—epilepsy syndrome	0.00852	0.0261	CbGbCtD
Dihydroergotamine—CYP3A4—Phenobarbital—epilepsy syndrome	0.00814	0.0249	CbGbCtD
Dihydroergotamine—CYP3A4—Acetazolamide—epilepsy syndrome	0.00814	0.0249	CbGbCtD
Dihydroergotamine—CYP3A4—Midazolam—epilepsy syndrome	0.00803	0.0246	CbGbCtD
Dihydroergotamine—CYP3A4—Diazepam—epilepsy syndrome	0.00772	0.0236	CbGbCtD
Dihydroergotamine—CYP3A4—Zonisamide—epilepsy syndrome	0.00753	0.0231	CbGbCtD
Dihydroergotamine—CYP3A4—Valproic Acid—epilepsy syndrome	0.00608	0.0186	CbGbCtD
Dihydroergotamine—CYP3A4—Topiramate—epilepsy syndrome	0.00549	0.0168	CbGbCtD
Dihydroergotamine—HTR6—ganglion—epilepsy syndrome	0.00298	0.0545	CbGeAlD
Dihydroergotamine—HTR1B—telencephalic ventricle—epilepsy syndrome	0.00289	0.0528	CbGeAlD
Dihydroergotamine—HTR1D—telencephalic ventricle—epilepsy syndrome	0.0028	0.0511	CbGeAlD
Dihydroergotamine—HTR1A—telencephalic ventricle—epilepsy syndrome	0.00233	0.0426	CbGeAlD
Dihydroergotamine—HTR1B—ganglion—epilepsy syndrome	0.0018	0.0329	CbGeAlD
Dihydroergotamine—HTR1D—ganglion—epilepsy syndrome	0.00174	0.0318	CbGeAlD
Dihydroergotamine—HTR1A—ganglion—epilepsy syndrome	0.00145	0.0265	CbGeAlD
Dihydroergotamine—HTR6—forebrain—epilepsy syndrome	0.00125	0.0229	CbGeAlD
Dihydroergotamine—HTR6—telencephalon—epilepsy syndrome	0.00115	0.021	CbGeAlD
Dihydroergotamine—HTR1A—hindbrain—epilepsy syndrome	0.0011	0.0201	CbGeAlD
Dihydroergotamine—HTR1B—brainstem—epilepsy syndrome	0.000781	0.0143	CbGeAlD
Dihydroergotamine—HTR1D—brainstem—epilepsy syndrome	0.000756	0.0138	CbGeAlD
Dihydroergotamine—HTR1B—forebrain—epilepsy syndrome	0.000754	0.0138	CbGeAlD
Dihydroergotamine—HTR1D—forebrain—epilepsy syndrome	0.00073	0.0134	CbGeAlD
Dihydroergotamine—HTR6—head—epilepsy syndrome	0.000716	0.0131	CbGeAlD
Dihydroergotamine—HTR1B—telencephalon—epilepsy syndrome	0.000693	0.0127	CbGeAlD
Dihydroergotamine—HTR6—nervous system—epilepsy syndrome	0.000679	0.0124	CbGeAlD
Dihydroergotamine—HTR2B—forebrain—epilepsy syndrome	0.000679	0.0124	CbGeAlD
Dihydroergotamine—HTR1D—telencephalon—epilepsy syndrome	0.000671	0.0123	CbGeAlD
Dihydroergotamine—HTR6—central nervous system—epilepsy syndrome	0.000654	0.012	CbGeAlD
Dihydroergotamine—HTR1A—brainstem—epilepsy syndrome	0.00063	0.0115	CbGeAlD
Dihydroergotamine—HTR2B—telencephalon—epilepsy syndrome	0.000624	0.0114	CbGeAlD
Dihydroergotamine—HTR1A—forebrain—epilepsy syndrome	0.000608	0.0111	CbGeAlD
Dihydroergotamine—HTR1A—telencephalon—epilepsy syndrome	0.000559	0.0102	CbGeAlD
Dihydroergotamine—HTR6—brain—epilepsy syndrome	0.000519	0.00949	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR7—epilepsy syndrome	0.0005	0.225	CrCbGaD
Dihydroergotamine—HTR1B—midbrain—epilepsy syndrome	0.000498	0.00911	CbGeAlD
Dihydroergotamine—HTR1B—spinal cord—epilepsy syndrome	0.000486	0.00889	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—epilepsy syndrome	0.000482	0.00882	CbGeAlD
Dihydroergotamine—Ergotamine—ADRA2A—epilepsy syndrome	0.000445	0.2	CrCbGaD
Dihydroergotamine—HTR1B—head—epilepsy syndrome	0.000432	0.0079	CbGeAlD
Dihydroergotamine—Bromocriptine—ADRA2A—epilepsy syndrome	0.000429	0.193	CrCbGaD
Dihydroergotamine—ADRA2A—forebrain—epilepsy syndrome	0.000426	0.0078	CbGeAlD
Dihydroergotamine—HTR1D—head—epilepsy syndrome	0.000418	0.00765	CbGeAlD
Dihydroergotamine—HTR1B—nervous system—epilepsy syndrome	0.000409	0.00749	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—epilepsy syndrome	0.000402	0.00735	CbGeAlD
Dihydroergotamine—HTR1D—nervous system—epilepsy syndrome	0.000396	0.00725	CbGeAlD
Dihydroergotamine—HTR1B—central nervous system—epilepsy syndrome	0.000394	0.00721	CbGeAlD
Dihydroergotamine—ADRA2A—telencephalon—epilepsy syndrome	0.000392	0.00717	CbGeAlD
Dihydroergotamine—HTR1A—spinal cord—epilepsy syndrome	0.000392	0.00717	CbGeAlD
Dihydroergotamine—HTR2B—head—epilepsy syndrome	0.000389	0.00711	CbGeAlD
Dihydroergotamine—HTR1D—central nervous system—epilepsy syndrome	0.000382	0.00698	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—epilepsy syndrome	0.000369	0.00674	CbGeAlD
Dihydroergotamine—HTR2B—central nervous system—epilepsy syndrome	0.000355	0.00649	CbGeAlD
Dihydroergotamine—HTR1A—head—epilepsy syndrome	0.000348	0.00637	CbGeAlD
Dihydroergotamine—HTR1A—nervous system—epilepsy syndrome	0.00033	0.00604	CbGeAlD
Dihydroergotamine—HTR1A—central nervous system—epilepsy syndrome	0.000318	0.00582	CbGeAlD
Dihydroergotamine—HTR1B—brain—epilepsy syndrome	0.000313	0.00572	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—epilepsy syndrome	0.000311	0.00569	CbGeAlD
Dihydroergotamine—ADRA2A—medulla oblongata—epilepsy syndrome	0.000308	0.00564	CbGeAlD
Dihydroergotamine—HTR1D—brain—epilepsy syndrome	0.000303	0.00554	CbGeAlD
Dihydroergotamine—HTR2B—brain—epilepsy syndrome	0.000282	0.00515	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—epilepsy syndrome	0.000282	0.00515	CbGeAlD
Dihydroergotamine—ADRA2A—spinal cord—epilepsy syndrome	0.000275	0.00503	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—epilepsy syndrome	0.000261	0.117	CrCbGaD
Dihydroergotamine—HTR1A—brain—epilepsy syndrome	0.000252	0.00462	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR2A—epilepsy syndrome	0.000252	0.113	CrCbGaD
Dihydroergotamine—ADRA2A—head—epilepsy syndrome	0.000244	0.00447	CbGeAlD
Dihydroergotamine—ABCB1—forebrain—epilepsy syndrome	0.000238	0.00435	CbGeAlD
Dihydroergotamine—ADRA2A—nervous system—epilepsy syndrome	0.000232	0.00423	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—epilepsy syndrome	0.000223	0.00408	CbGeAlD
Dihydroergotamine—ABCB1—telencephalon—epilepsy syndrome	0.000219	0.004	CbGeAlD
Dihydroergotamine—ADRA2A—cerebellum—epilepsy syndrome	0.000218	0.00398	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—epilepsy syndrome	0.000182	0.00333	CbGeAlD
Dihydroergotamine—ADRA2A—brain—epilepsy syndrome	0.000177	0.00324	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—epilepsy syndrome	0.000175	0.00321	CbGeAlD
Dihydroergotamine—ABCB1—medulla oblongata—epilepsy syndrome	0.000172	0.00314	CbGeAlD
Dihydroergotamine—Ergotamine—ABCB1—epilepsy syndrome	0.00017	0.0767	CrCbGaD
Dihydroergotamine—Bromocriptine—ABCB1—epilepsy syndrome	0.000164	0.0739	CrCbGaD
Dihydroergotamine—ABCB1—midbrain—epilepsy syndrome	0.000157	0.00287	CbGeAlD
Dihydroergotamine—ABCB1—spinal cord—epilepsy syndrome	0.000153	0.0028	CbGeAlD
Dihydroergotamine—ABCB1—head—epilepsy syndrome	0.000136	0.00249	CbGeAlD
Dihydroergotamine—ABCB1—nervous system—epilepsy syndrome	0.000129	0.00236	CbGeAlD
Dihydroergotamine—ABCB1—central nervous system—epilepsy syndrome	0.000124	0.00227	CbGeAlD
Dihydroergotamine—ABCB1—cerebellum—epilepsy syndrome	0.000121	0.00222	CbGeAlD
Dihydroergotamine—ABCB1—brain—epilepsy syndrome	9.86e-05	0.0018	CbGeAlD
Dihydroergotamine—Urticaria—Lamotrigine—epilepsy syndrome	6.77e-05	0.000337	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	6.77e-05	0.000337	CcSEcCtD
Dihydroergotamine—Malaise—Pregabalin—epilepsy syndrome	6.76e-05	0.000336	CcSEcCtD
Dihydroergotamine—Nausea—Propofol—epilepsy syndrome	6.76e-05	0.000336	CcSEcCtD
Dihydroergotamine—Tension—Gabapentin—epilepsy syndrome	6.75e-05	0.000336	CcSEcCtD
Dihydroergotamine—Vomiting—Fosphenytoin—epilepsy syndrome	6.75e-05	0.000336	CcSEcCtD
Dihydroergotamine—Diarrhoea—Felbamate—epilepsy syndrome	6.74e-05	0.000335	CcSEcCtD
Dihydroergotamine—Vertigo—Pregabalin—epilepsy syndrome	6.74e-05	0.000335	CcSEcCtD
Dihydroergotamine—Abdominal pain—Lamotrigine—epilepsy syndrome	6.74e-05	0.000335	CcSEcCtD
Dihydroergotamine—Body temperature increased—Lamotrigine—epilepsy syndrome	6.74e-05	0.000335	CcSEcCtD
Dihydroergotamine—Dizziness—Diazepam—epilepsy syndrome	6.74e-05	0.000335	CcSEcCtD
Dihydroergotamine—Rash—Fosphenytoin—epilepsy syndrome	6.69e-05	0.000333	CcSEcCtD
Dihydroergotamine—Dermatitis—Fosphenytoin—epilepsy syndrome	6.69e-05	0.000332	CcSEcCtD
Dihydroergotamine—Nervousness—Gabapentin—epilepsy syndrome	6.68e-05	0.000332	CcSEcCtD
Dihydroergotamine—Asthenia—Clonazepam—epilepsy syndrome	6.67e-05	0.000332	CcSEcCtD
Dihydroergotamine—Rhinitis—Topiramate—epilepsy syndrome	6.66e-05	0.000331	CcSEcCtD
Dihydroergotamine—Headache—Fosphenytoin—epilepsy syndrome	6.65e-05	0.000331	CcSEcCtD
Dihydroergotamine—Palpitations—Pregabalin—epilepsy syndrome	6.63e-05	0.00033	CcSEcCtD
Dihydroergotamine—Asthenia—Phenytoin—epilepsy syndrome	6.63e-05	0.00033	CcSEcCtD
Dihydroergotamine—Nausea—Midazolam—epilepsy syndrome	6.61e-05	0.000329	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Topiramate—epilepsy syndrome	6.61e-05	0.000329	CcSEcCtD
Dihydroergotamine—Muscle spasms—Gabapentin—epilepsy syndrome	6.61e-05	0.000329	CcSEcCtD
Dihydroergotamine—Tachycardia—Valproic Acid—epilepsy syndrome	6.61e-05	0.000329	CcSEcCtD
Dihydroergotamine—Diarrhoea—Zonisamide—epilepsy syndrome	6.6e-05	0.000328	CcSEcCtD
Dihydroergotamine—Pharyngitis—Topiramate—epilepsy syndrome	6.6e-05	0.000328	CcSEcCtD
Dihydroergotamine—Asthenia—Oxcarbazepine—epilepsy syndrome	6.59e-05	0.000328	CcSEcCtD
Dihydroergotamine—Pruritus—Clonazepam—epilepsy syndrome	6.58e-05	0.000327	CcSEcCtD
Dihydroergotamine—Vomiting—Vigabatrin—epilepsy syndrome	6.58e-05	0.000327	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Valproic Acid—epilepsy syndrome	6.55e-05	0.000325	CcSEcCtD
Dihydroergotamine—Pruritus—Phenytoin—epilepsy syndrome	6.54e-05	0.000325	CcSEcCtD
Dihydroergotamine—Nausea—Levetiracetam—epilepsy syndrome	6.53e-05	0.000325	CcSEcCtD
Dihydroergotamine—Rash—Vigabatrin—epilepsy syndrome	6.52e-05	0.000324	CcSEcCtD
Dihydroergotamine—Dizziness—Felbamate—epilepsy syndrome	6.52e-05	0.000324	CcSEcCtD
Dihydroergotamine—Dermatitis—Vigabatrin—epilepsy syndrome	6.52e-05	0.000324	CcSEcCtD
Dihydroergotamine—Pruritus—Oxcarbazepine—epilepsy syndrome	6.5e-05	0.000323	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Carbamazepine—epilepsy syndrome	6.5e-05	0.000323	CcSEcCtD
Dihydroergotamine—Headache—Vigabatrin—epilepsy syndrome	6.48e-05	0.000322	CcSEcCtD
Dihydroergotamine—Hypertension—Pregabalin—epilepsy syndrome	6.48e-05	0.000322	CcSEcCtD
Dihydroergotamine—Vomiting—Diazepam—epilepsy syndrome	6.48e-05	0.000322	CcSEcCtD
Dihydroergotamine—Anorexia—Valproic Acid—epilepsy syndrome	6.45e-05	0.000321	CcSEcCtD
Dihydroergotamine—Tremor—Gabapentin—epilepsy syndrome	6.44e-05	0.00032	CcSEcCtD
Dihydroergotamine—Rash—Diazepam—epilepsy syndrome	6.42e-05	0.000319	CcSEcCtD
Dihydroergotamine—Dermatitis—Diazepam—epilepsy syndrome	6.42e-05	0.000319	CcSEcCtD
Dihydroergotamine—Visual impairment—Topiramate—epilepsy syndrome	6.41e-05	0.000319	CcSEcCtD
Dihydroergotamine—Arthralgia—Pregabalin—epilepsy syndrome	6.39e-05	0.000318	CcSEcCtD
Dihydroergotamine—Myalgia—Pregabalin—epilepsy syndrome	6.39e-05	0.000318	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Gabapentin—epilepsy syndrome	6.38e-05	0.000317	CcSEcCtD
Dihydroergotamine—Dizziness—Zonisamide—epilepsy syndrome	6.38e-05	0.000317	CcSEcCtD
Dihydroergotamine—Headache—Diazepam—epilepsy syndrome	6.38e-05	0.000317	CcSEcCtD
Dihydroergotamine—Anxiety—Pregabalin—epilepsy syndrome	6.36e-05	0.000316	CcSEcCtD
Dihydroergotamine—Diarrhoea—Clonazepam—epilepsy syndrome	6.36e-05	0.000316	CcSEcCtD
Dihydroergotamine—Hypotension—Valproic Acid—epilepsy syndrome	6.33e-05	0.000315	CcSEcCtD
Dihydroergotamine—Asthenia—Carbamazepine—epilepsy syndrome	6.33e-05	0.000315	CcSEcCtD
Dihydroergotamine—Agitation—Gabapentin—epilepsy syndrome	6.32e-05	0.000314	CcSEcCtD
Dihydroergotamine—Diarrhoea—Phenytoin—epilepsy syndrome	6.32e-05	0.000314	CcSEcCtD
Dihydroergotamine—Discomfort—Pregabalin—epilepsy syndrome	6.31e-05	0.000314	CcSEcCtD
Dihydroergotamine—Nausea—Fosphenytoin—epilepsy syndrome	6.3e-05	0.000313	CcSEcCtD
Dihydroergotamine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	6.29e-05	0.000313	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Lamotrigine—epilepsy syndrome	6.28e-05	0.000312	CcSEcCtD
Dihydroergotamine—Vomiting—Felbamate—epilepsy syndrome	6.27e-05	0.000312	CcSEcCtD
Dihydroergotamine—Dry mouth—Pregabalin—epilepsy syndrome	6.25e-05	0.000311	CcSEcCtD
Dihydroergotamine—Pruritus—Carbamazepine—epilepsy syndrome	6.24e-05	0.00031	CcSEcCtD
Dihydroergotamine—Rash—Felbamate—epilepsy syndrome	6.22e-05	0.000309	CcSEcCtD
Dihydroergotamine—Dermatitis—Felbamate—epilepsy syndrome	6.21e-05	0.000309	CcSEcCtD
Dihydroergotamine—Malaise—Gabapentin—epilepsy syndrome	6.2e-05	0.000308	CcSEcCtD
Dihydroergotamine—Tinnitus—Topiramate—epilepsy syndrome	6.2e-05	0.000308	CcSEcCtD
Dihydroergotamine—Vertigo—Gabapentin—epilepsy syndrome	6.18e-05	0.000307	CcSEcCtD
Dihydroergotamine—Headache—Felbamate—epilepsy syndrome	6.18e-05	0.000307	CcSEcCtD
Dihydroergotamine—Confusional state—Pregabalin—epilepsy syndrome	6.17e-05	0.000307	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	6.17e-05	0.000307	CcSEcCtD
Dihydroergotamine—Flushing—Topiramate—epilepsy syndrome	6.17e-05	0.000307	CcSEcCtD
Dihydroergotamine—Dizziness—Clonazepam—epilepsy syndrome	6.15e-05	0.000306	CcSEcCtD
Dihydroergotamine—Nausea—Vigabatrin—epilepsy syndrome	6.15e-05	0.000306	CcSEcCtD
Dihydroergotamine—Vomiting—Zonisamide—epilepsy syndrome	6.14e-05	0.000305	CcSEcCtD
Dihydroergotamine—Insomnia—Valproic Acid—epilepsy syndrome	6.12e-05	0.000305	CcSEcCtD
Dihydroergotamine—Oedema—Pregabalin—epilepsy syndrome	6.12e-05	0.000304	CcSEcCtD
Dihydroergotamine—Asthenia—Lamotrigine—epilepsy syndrome	6.11e-05	0.000304	CcSEcCtD
Dihydroergotamine—Dizziness—Phenytoin—epilepsy syndrome	6.11e-05	0.000304	CcSEcCtD
Dihydroergotamine—Rash—Zonisamide—epilepsy syndrome	6.08e-05	0.000302	CcSEcCtD
Dihydroergotamine—Paraesthesia—Valproic Acid—epilepsy syndrome	6.08e-05	0.000302	CcSEcCtD
Dihydroergotamine—Palpitations—Gabapentin—epilepsy syndrome	6.08e-05	0.000302	CcSEcCtD
Dihydroergotamine—Dermatitis—Zonisamide—epilepsy syndrome	6.08e-05	0.000302	CcSEcCtD
Dihydroergotamine—Dizziness—Oxcarbazepine—epilepsy syndrome	6.08e-05	0.000302	CcSEcCtD
Dihydroergotamine—Nausea—Diazepam—epilepsy syndrome	6.05e-05	0.000301	CcSEcCtD
Dihydroergotamine—Headache—Zonisamide—epilepsy syndrome	6.04e-05	0.000301	CcSEcCtD
Dihydroergotamine—Dyspnoea—Valproic Acid—epilepsy syndrome	6.04e-05	0.0003	CcSEcCtD
Dihydroergotamine—Diarrhoea—Carbamazepine—epilepsy syndrome	6.03e-05	0.0003	CcSEcCtD
Dihydroergotamine—Pruritus—Lamotrigine—epilepsy syndrome	6.03e-05	0.0003	CcSEcCtD
Dihydroergotamine—Shock—Pregabalin—epilepsy syndrome	6.02e-05	0.000299	CcSEcCtD
Dihydroergotamine—Somnolence—Valproic Acid—epilepsy syndrome	6.02e-05	0.000299	CcSEcCtD
Dihydroergotamine—Tachycardia—Pregabalin—epilepsy syndrome	5.97e-05	0.000297	CcSEcCtD
Dihydroergotamine—Chills—Topiramate—epilepsy syndrome	5.96e-05	0.000297	CcSEcCtD
Dihydroergotamine—Dyspepsia—Valproic Acid—epilepsy syndrome	5.96e-05	0.000296	CcSEcCtD
Dihydroergotamine—Hypertension—Gabapentin—epilepsy syndrome	5.94e-05	0.000295	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Pregabalin—epilepsy syndrome	5.92e-05	0.000294	CcSEcCtD
Dihydroergotamine—Vomiting—Clonazepam—epilepsy syndrome	5.91e-05	0.000294	CcSEcCtD
Dihydroergotamine—Decreased appetite—Valproic Acid—epilepsy syndrome	5.89e-05	0.000293	CcSEcCtD
Dihydroergotamine—Vomiting—Phenytoin—epilepsy syndrome	5.87e-05	0.000292	CcSEcCtD
Dihydroergotamine—Rash—Clonazepam—epilepsy syndrome	5.86e-05	0.000292	CcSEcCtD
Dihydroergotamine—Dermatitis—Clonazepam—epilepsy syndrome	5.86e-05	0.000291	CcSEcCtD
Dihydroergotamine—Arthralgia—Gabapentin—epilepsy syndrome	5.86e-05	0.000291	CcSEcCtD
Dihydroergotamine—Myalgia—Gabapentin—epilepsy syndrome	5.86e-05	0.000291	CcSEcCtD
Dihydroergotamine—Nausea—Felbamate—epilepsy syndrome	5.86e-05	0.000291	CcSEcCtD
Dihydroergotamine—Vomiting—Oxcarbazepine—epilepsy syndrome	5.84e-05	0.00029	CcSEcCtD
Dihydroergotamine—Fatigue—Valproic Acid—epilepsy syndrome	5.84e-05	0.00029	CcSEcCtD
Dihydroergotamine—Anxiety—Gabapentin—epilepsy syndrome	5.84e-05	0.00029	CcSEcCtD
Dihydroergotamine—Anorexia—Pregabalin—epilepsy syndrome	5.84e-05	0.00029	CcSEcCtD
Dihydroergotamine—Dizziness—Carbamazepine—epilepsy syndrome	5.83e-05	0.00029	CcSEcCtD
Dihydroergotamine—Diarrhoea—Lamotrigine—epilepsy syndrome	5.83e-05	0.00029	CcSEcCtD
Dihydroergotamine—Headache—Clonazepam—epilepsy syndrome	5.83e-05	0.00029	CcSEcCtD
Dihydroergotamine—Rash—Phenytoin—epilepsy syndrome	5.82e-05	0.00029	CcSEcCtD
Dihydroergotamine—Dermatitis—Phenytoin—epilepsy syndrome	5.82e-05	0.000289	CcSEcCtD
Dihydroergotamine—Rash—Oxcarbazepine—epilepsy syndrome	5.79e-05	0.000288	CcSEcCtD
Dihydroergotamine—Pain—Valproic Acid—epilepsy syndrome	5.79e-05	0.000288	CcSEcCtD
Dihydroergotamine—Dermatitis—Oxcarbazepine—epilepsy syndrome	5.79e-05	0.000288	CcSEcCtD
Dihydroergotamine—Headache—Phenytoin—epilepsy syndrome	5.79e-05	0.000288	CcSEcCtD
Dihydroergotamine—Discomfort—Gabapentin—epilepsy syndrome	5.79e-05	0.000288	CcSEcCtD
Dihydroergotamine—Headache—Oxcarbazepine—epilepsy syndrome	5.76e-05	0.000286	CcSEcCtD
Dihydroergotamine—Nausea—Zonisamide—epilepsy syndrome	5.73e-05	0.000285	CcSEcCtD
Dihydroergotamine—Dry mouth—Gabapentin—epilepsy syndrome	5.73e-05	0.000285	CcSEcCtD
Dihydroergotamine—Hypotension—Pregabalin—epilepsy syndrome	5.72e-05	0.000284	CcSEcCtD
Dihydroergotamine—Tension—Topiramate—epilepsy syndrome	5.68e-05	0.000282	CcSEcCtD
Dihydroergotamine—Confusional state—Gabapentin—epilepsy syndrome	5.66e-05	0.000281	CcSEcCtD
Dihydroergotamine—Dizziness—Lamotrigine—epilepsy syndrome	5.64e-05	0.00028	CcSEcCtD
Dihydroergotamine—Nervousness—Topiramate—epilepsy syndrome	5.62e-05	0.000279	CcSEcCtD
Dihydroergotamine—Oedema—Gabapentin—epilepsy syndrome	5.61e-05	0.000279	CcSEcCtD
Dihydroergotamine—Vomiting—Carbamazepine—epilepsy syndrome	5.61e-05	0.000279	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Valproic Acid—epilepsy syndrome	5.58e-05	0.000277	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	5.58e-05	0.000277	CcSEcCtD
Dihydroergotamine—Muscle spasms—Topiramate—epilepsy syndrome	5.56e-05	0.000277	CcSEcCtD
Dihydroergotamine—Rash—Carbamazepine—epilepsy syndrome	5.56e-05	0.000276	CcSEcCtD
Dihydroergotamine—Dermatitis—Carbamazepine—epilepsy syndrome	5.55e-05	0.000276	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	5.54e-05	0.000275	CcSEcCtD
Dihydroergotamine—Insomnia—Pregabalin—epilepsy syndrome	5.54e-05	0.000275	CcSEcCtD
Dihydroergotamine—Nausea—Clonazepam—epilepsy syndrome	5.52e-05	0.000275	CcSEcCtD
Dihydroergotamine—Headache—Carbamazepine—epilepsy syndrome	5.52e-05	0.000275	CcSEcCtD
Dihydroergotamine—Shock—Gabapentin—epilepsy syndrome	5.52e-05	0.000275	CcSEcCtD
Dihydroergotamine—Paraesthesia—Pregabalin—epilepsy syndrome	5.5e-05	0.000273	CcSEcCtD
Dihydroergotamine—Nausea—Phenytoin—epilepsy syndrome	5.49e-05	0.000273	CcSEcCtD
Dihydroergotamine—Tachycardia—Gabapentin—epilepsy syndrome	5.48e-05	0.000272	CcSEcCtD
Dihydroergotamine—Dyspnoea—Pregabalin—epilepsy syndrome	5.46e-05	0.000271	CcSEcCtD
Dihydroergotamine—Nausea—Oxcarbazepine—epilepsy syndrome	5.46e-05	0.000271	CcSEcCtD
Dihydroergotamine—Somnolence—Pregabalin—epilepsy syndrome	5.44e-05	0.000271	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Gabapentin—epilepsy syndrome	5.43e-05	0.00027	CcSEcCtD
Dihydroergotamine—Tremor—Topiramate—epilepsy syndrome	5.42e-05	0.00027	CcSEcCtD
Dihydroergotamine—Vomiting—Lamotrigine—epilepsy syndrome	5.42e-05	0.000269	CcSEcCtD
Dihydroergotamine—Urticaria—Valproic Acid—epilepsy syndrome	5.38e-05	0.000267	CcSEcCtD
Dihydroergotamine—Rash—Lamotrigine—epilepsy syndrome	5.37e-05	0.000267	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Topiramate—epilepsy syndrome	5.37e-05	0.000267	CcSEcCtD
Dihydroergotamine—Dermatitis—Lamotrigine—epilepsy syndrome	5.37e-05	0.000267	CcSEcCtD
Dihydroergotamine—Abdominal pain—Valproic Acid—epilepsy syndrome	5.35e-05	0.000266	CcSEcCtD
Dihydroergotamine—Body temperature increased—Valproic Acid—epilepsy syndrome	5.35e-05	0.000266	CcSEcCtD
Dihydroergotamine—Anorexia—Gabapentin—epilepsy syndrome	5.35e-05	0.000266	CcSEcCtD
Dihydroergotamine—Headache—Lamotrigine—epilepsy syndrome	5.34e-05	0.000265	CcSEcCtD
Dihydroergotamine—Decreased appetite—Pregabalin—epilepsy syndrome	5.32e-05	0.000265	CcSEcCtD
Dihydroergotamine—Agitation—Topiramate—epilepsy syndrome	5.32e-05	0.000264	CcSEcCtD
Dihydroergotamine—Fatigue—Pregabalin—epilepsy syndrome	5.28e-05	0.000262	CcSEcCtD
Dihydroergotamine—Hypotension—Gabapentin—epilepsy syndrome	5.25e-05	0.000261	CcSEcCtD
Dihydroergotamine—Nausea—Carbamazepine—epilepsy syndrome	5.24e-05	0.00026	CcSEcCtD
Dihydroergotamine—Pain—Pregabalin—epilepsy syndrome	5.24e-05	0.00026	CcSEcCtD
Dihydroergotamine—Malaise—Topiramate—epilepsy syndrome	5.22e-05	0.000259	CcSEcCtD
Dihydroergotamine—Vertigo—Topiramate—epilepsy syndrome	5.2e-05	0.000258	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	5.11e-05	0.000254	CcSEcCtD
Dihydroergotamine—Palpitations—Topiramate—epilepsy syndrome	5.11e-05	0.000254	CcSEcCtD
Dihydroergotamine—Insomnia—Gabapentin—epilepsy syndrome	5.08e-05	0.000252	CcSEcCtD
Dihydroergotamine—Nausea—Lamotrigine—epilepsy syndrome	5.06e-05	0.000252	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Pregabalin—epilepsy syndrome	5.04e-05	0.000251	CcSEcCtD
Dihydroergotamine—Paraesthesia—Gabapentin—epilepsy syndrome	5.04e-05	0.000251	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	5.01e-05	0.000249	CcSEcCtD
Dihydroergotamine—Dyspnoea—Gabapentin—epilepsy syndrome	5e-05	0.000249	CcSEcCtD
Dihydroergotamine—Hypertension—Topiramate—epilepsy syndrome	5e-05	0.000248	CcSEcCtD
Dihydroergotamine—Somnolence—Gabapentin—epilepsy syndrome	4.99e-05	0.000248	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Valproic Acid—epilepsy syndrome	4.99e-05	0.000248	CcSEcCtD
Dihydroergotamine—Dyspepsia—Gabapentin—epilepsy syndrome	4.94e-05	0.000246	CcSEcCtD
Dihydroergotamine—Myalgia—Topiramate—epilepsy syndrome	4.93e-05	0.000245	CcSEcCtD
Dihydroergotamine—Arthralgia—Topiramate—epilepsy syndrome	4.93e-05	0.000245	CcSEcCtD
Dihydroergotamine—Anxiety—Topiramate—epilepsy syndrome	4.91e-05	0.000244	CcSEcCtD
Dihydroergotamine—Decreased appetite—Gabapentin—epilepsy syndrome	4.88e-05	0.000243	CcSEcCtD
Dihydroergotamine—Discomfort—Topiramate—epilepsy syndrome	4.87e-05	0.000242	CcSEcCtD
Dihydroergotamine—Urticaria—Pregabalin—epilepsy syndrome	4.86e-05	0.000242	CcSEcCtD
Dihydroergotamine—Asthenia—Valproic Acid—epilepsy syndrome	4.86e-05	0.000242	CcSEcCtD
Dihydroergotamine—Fatigue—Gabapentin—epilepsy syndrome	4.84e-05	0.000241	CcSEcCtD
Dihydroergotamine—Body temperature increased—Pregabalin—epilepsy syndrome	4.84e-05	0.000241	CcSEcCtD
Dihydroergotamine—Abdominal pain—Pregabalin—epilepsy syndrome	4.84e-05	0.000241	CcSEcCtD
Dihydroergotamine—Dry mouth—Topiramate—epilepsy syndrome	4.82e-05	0.00024	CcSEcCtD
Dihydroergotamine—Pain—Gabapentin—epilepsy syndrome	4.8e-05	0.000239	CcSEcCtD
Dihydroergotamine—Pruritus—Valproic Acid—epilepsy syndrome	4.79e-05	0.000238	CcSEcCtD
Dihydroergotamine—Confusional state—Topiramate—epilepsy syndrome	4.76e-05	0.000237	CcSEcCtD
Dihydroergotamine—Oedema—Topiramate—epilepsy syndrome	4.72e-05	0.000235	CcSEcCtD
Dihydroergotamine—Shock—Topiramate—epilepsy syndrome	4.65e-05	0.000231	CcSEcCtD
Dihydroergotamine—Diarrhoea—Valproic Acid—epilepsy syndrome	4.63e-05	0.00023	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gabapentin—epilepsy syndrome	4.63e-05	0.00023	CcSEcCtD
Dihydroergotamine—Tachycardia—Topiramate—epilepsy syndrome	4.61e-05	0.000229	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	4.59e-05	0.000228	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Topiramate—epilepsy syndrome	4.57e-05	0.000227	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Pregabalin—epilepsy syndrome	4.51e-05	0.000224	CcSEcCtD
Dihydroergotamine—Anorexia—Topiramate—epilepsy syndrome	4.5e-05	0.000224	CcSEcCtD
Dihydroergotamine—Dizziness—Valproic Acid—epilepsy syndrome	4.48e-05	0.000223	CcSEcCtD
Dihydroergotamine—Urticaria—Gabapentin—epilepsy syndrome	4.46e-05	0.000222	CcSEcCtD
Dihydroergotamine—Abdominal pain—Gabapentin—epilepsy syndrome	4.44e-05	0.000221	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gabapentin—epilepsy syndrome	4.44e-05	0.000221	CcSEcCtD
Dihydroergotamine—Hypotension—Topiramate—epilepsy syndrome	4.41e-05	0.000219	CcSEcCtD
Dihydroergotamine—Asthenia—Pregabalin—epilepsy syndrome	4.39e-05	0.000218	CcSEcCtD
Dihydroergotamine—Pruritus—Pregabalin—epilepsy syndrome	4.33e-05	0.000215	CcSEcCtD
Dihydroergotamine—Vomiting—Valproic Acid—epilepsy syndrome	4.31e-05	0.000214	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	4.3e-05	0.000214	CcSEcCtD
Dihydroergotamine—Insomnia—Topiramate—epilepsy syndrome	4.27e-05	0.000212	CcSEcCtD
Dihydroergotamine—Rash—Valproic Acid—epilepsy syndrome	4.27e-05	0.000212	CcSEcCtD
Dihydroergotamine—Dermatitis—Valproic Acid—epilepsy syndrome	4.27e-05	0.000212	CcSEcCtD
Dihydroergotamine—Headache—Valproic Acid—epilepsy syndrome	4.24e-05	0.000211	CcSEcCtD
Dihydroergotamine—Paraesthesia—Topiramate—epilepsy syndrome	4.24e-05	0.000211	CcSEcCtD
Dihydroergotamine—Dyspnoea—Topiramate—epilepsy syndrome	4.21e-05	0.000209	CcSEcCtD
Dihydroergotamine—Somnolence—Topiramate—epilepsy syndrome	4.2e-05	0.000209	CcSEcCtD
Dihydroergotamine—Diarrhoea—Pregabalin—epilepsy syndrome	4.19e-05	0.000208	CcSEcCtD
Dihydroergotamine—Dyspepsia—Topiramate—epilepsy syndrome	4.16e-05	0.000207	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Gabapentin—epilepsy syndrome	4.14e-05	0.000206	CcSEcCtD
Dihydroergotamine—Decreased appetite—Topiramate—epilepsy syndrome	4.11e-05	0.000204	CcSEcCtD
Dihydroergotamine—Fatigue—Topiramate—epilepsy syndrome	4.07e-05	0.000202	CcSEcCtD
Dihydroergotamine—Dizziness—Pregabalin—epilepsy syndrome	4.05e-05	0.000201	CcSEcCtD
Dihydroergotamine—Pain—Topiramate—epilepsy syndrome	4.04e-05	0.000201	CcSEcCtD
Dihydroergotamine—Asthenia—Gabapentin—epilepsy syndrome	4.03e-05	0.0002	CcSEcCtD
Dihydroergotamine—Nausea—Valproic Acid—epilepsy syndrome	4.02e-05	0.0002	CcSEcCtD
Dihydroergotamine—Pruritus—Gabapentin—epilepsy syndrome	3.97e-05	0.000197	CcSEcCtD
Dihydroergotamine—Vomiting—Pregabalin—epilepsy syndrome	3.89e-05	0.000194	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Topiramate—epilepsy syndrome	3.89e-05	0.000194	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Topiramate—epilepsy syndrome	3.86e-05	0.000192	CcSEcCtD
Dihydroergotamine—Rash—Pregabalin—epilepsy syndrome	3.86e-05	0.000192	CcSEcCtD
Dihydroergotamine—Dermatitis—Pregabalin—epilepsy syndrome	3.86e-05	0.000192	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gabapentin—epilepsy syndrome	3.84e-05	0.000191	CcSEcCtD
Dihydroergotamine—Headache—Pregabalin—epilepsy syndrome	3.84e-05	0.000191	CcSEcCtD
Dihydroergotamine—Urticaria—Topiramate—epilepsy syndrome	3.75e-05	0.000187	CcSEcCtD
Dihydroergotamine—Abdominal pain—Topiramate—epilepsy syndrome	3.73e-05	0.000186	CcSEcCtD
Dihydroergotamine—Body temperature increased—Topiramate—epilepsy syndrome	3.73e-05	0.000186	CcSEcCtD
Dihydroergotamine—Dizziness—Gabapentin—epilepsy syndrome	3.71e-05	0.000185	CcSEcCtD
Dihydroergotamine—Nausea—Pregabalin—epilepsy syndrome	3.64e-05	0.000181	CcSEcCtD
Dihydroergotamine—Vomiting—Gabapentin—epilepsy syndrome	3.57e-05	0.000177	CcSEcCtD
Dihydroergotamine—Rash—Gabapentin—epilepsy syndrome	3.54e-05	0.000176	CcSEcCtD
Dihydroergotamine—Dermatitis—Gabapentin—epilepsy syndrome	3.54e-05	0.000176	CcSEcCtD
Dihydroergotamine—Headache—Gabapentin—epilepsy syndrome	3.52e-05	0.000175	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Topiramate—epilepsy syndrome	3.48e-05	0.000173	CcSEcCtD
Dihydroergotamine—Asthenia—Topiramate—epilepsy syndrome	3.39e-05	0.000168	CcSEcCtD
Dihydroergotamine—Pruritus—Topiramate—epilepsy syndrome	3.34e-05	0.000166	CcSEcCtD
Dihydroergotamine—Nausea—Gabapentin—epilepsy syndrome	3.33e-05	0.000166	CcSEcCtD
Dihydroergotamine—Diarrhoea—Topiramate—epilepsy syndrome	3.23e-05	0.000161	CcSEcCtD
Dihydroergotamine—Dizziness—Topiramate—epilepsy syndrome	3.12e-05	0.000155	CcSEcCtD
Dihydroergotamine—Vomiting—Topiramate—epilepsy syndrome	3e-05	0.000149	CcSEcCtD
Dihydroergotamine—Rash—Topiramate—epilepsy syndrome	2.98e-05	0.000148	CcSEcCtD
Dihydroergotamine—Dermatitis—Topiramate—epilepsy syndrome	2.98e-05	0.000148	CcSEcCtD
Dihydroergotamine—Headache—Topiramate—epilepsy syndrome	2.96e-05	0.000147	CcSEcCtD
Dihydroergotamine—Nausea—Topiramate—epilepsy syndrome	2.81e-05	0.000139	CcSEcCtD
Dihydroergotamine—ADRA2A—Signaling Pathways—HSPB1—epilepsy syndrome	5.98e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL2—epilepsy syndrome	5.98e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CRH—epilepsy syndrome	5.98e-06	6.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PLCB1—epilepsy syndrome	5.95e-06	6.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCR5—epilepsy syndrome	5.94e-06	6.19e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—TH—epilepsy syndrome	5.93e-06	6.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FYN—epilepsy syndrome	5.91e-06	6.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT3—epilepsy syndrome	5.9e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCR5—epilepsy syndrome	5.9e-06	6.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—H2AFX—epilepsy syndrome	5.89e-06	6.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MEF2C—epilepsy syndrome	5.88e-06	6.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—epilepsy syndrome	5.87e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—epilepsy syndrome	5.86e-06	6.11e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCR5—epilepsy syndrome	5.82e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—epilepsy syndrome	5.82e-06	6.06e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	5.8e-06	6.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	5.77e-06	6.02e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ADAM10—epilepsy syndrome	5.77e-06	6.01e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CCL2—epilepsy syndrome	5.74e-06	5.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—epilepsy syndrome	5.7e-06	5.94e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—YWHAZ—epilepsy syndrome	5.68e-06	5.92e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	5.64e-06	5.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NGF—epilepsy syndrome	5.62e-06	5.86e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	5.57e-06	5.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TSC2—epilepsy syndrome	5.57e-06	5.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AGT—epilepsy syndrome	5.56e-06	5.8e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	5.56e-06	5.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	5.56e-06	5.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TSC2—epilepsy syndrome	5.53e-06	5.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AGT—epilepsy syndrome	5.52e-06	5.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NT5E—epilepsy syndrome	5.5e-06	5.73e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALAD—epilepsy syndrome	5.5e-06	5.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	5.48e-06	5.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCR5—epilepsy syndrome	5.47e-06	5.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—S100B—epilepsy syndrome	5.45e-06	5.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—APOE—epilepsy syndrome	5.45e-06	5.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TSC2—epilepsy syndrome	5.41e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	5.41e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	5.41e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—APOE—epilepsy syndrome	5.41e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	5.41e-06	5.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AGT—epilepsy syndrome	5.4e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SOCS3—epilepsy syndrome	5.4e-06	5.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDC42—epilepsy syndrome	5.39e-06	5.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	5.36e-06	5.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—epilepsy syndrome	5.35e-06	5.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—KDR—epilepsy syndrome	5.34e-06	5.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—KDR—epilepsy syndrome	5.3e-06	5.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—APOE—epilepsy syndrome	5.3e-06	5.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	5.27e-06	5.49e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ABCG2—epilepsy syndrome	5.26e-06	5.48e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	5.25e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	5.25e-06	5.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AVP—epilepsy syndrome	5.21e-06	5.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—KDR—epilepsy syndrome	5.19e-06	5.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—SRC—epilepsy syndrome	5.18e-06	5.4e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRKCB—epilepsy syndrome	5.14e-06	5.36e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	5.13e-06	5.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	5.13e-06	5.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6ST—epilepsy syndrome	5.12e-06	5.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRKCB—epilepsy syndrome	5.1e-06	5.31e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	5.09e-06	5.31e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	5.08e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	5.08e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TSC2—epilepsy syndrome	5.08e-06	5.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6ST—epilepsy syndrome	5.08e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	5.08e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AGT—epilepsy syndrome	5.08e-06	5.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	5.06e-06	5.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	5.05e-06	5.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	5.04e-06	5.25e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADSL—epilepsy syndrome	5.03e-06	5.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRKCB—epilepsy syndrome	4.99e-06	5.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	4.99e-06	5.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	4.99e-06	5.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—APOE—epilepsy syndrome	4.97e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6ST—epilepsy syndrome	4.97e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	4.97e-06	5.18e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	4.95e-06	5.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GLUL—epilepsy syndrome	4.93e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HES1—epilepsy syndrome	4.93e-06	5.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CAT—epilepsy syndrome	4.88e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—KDR—epilepsy syndrome	4.87e-06	5.08e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	4.87e-06	5.07e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	4.86e-06	5.06e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	4.84e-06	5.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FYN—epilepsy syndrome	4.8e-06	5e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—H2AFX—epilepsy syndrome	4.78e-06	4.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MEF2C—epilepsy syndrome	4.77e-06	4.97e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	4.75e-06	4.95e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	4.73e-06	4.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRKCB—epilepsy syndrome	4.69e-06	4.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—epilepsy syndrome	4.68e-06	4.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6ST—epilepsy syndrome	4.67e-06	4.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—epilepsy syndrome	4.65e-06	4.84e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	4.64e-06	4.83e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	4.61e-06	4.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—YWHAZ—epilepsy syndrome	4.61e-06	4.8e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	4.6e-06	4.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCL2—epilepsy syndrome	4.58e-06	4.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NGF—epilepsy syndrome	4.56e-06	4.75e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—epilepsy syndrome	4.55e-06	4.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCL2—epilepsy syndrome	4.55e-06	4.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	4.53e-06	4.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	4.53e-06	4.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	4.51e-06	4.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCL2—epilepsy syndrome	4.45e-06	4.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCR5—epilepsy syndrome	4.43e-06	4.62e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GPX1—epilepsy syndrome	4.41e-06	4.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AQP1—epilepsy syndrome	4.4e-06	4.58e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	4.38e-06	4.57e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	4.38e-06	4.56e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—BCHE—epilepsy syndrome	4.36e-06	4.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—epilepsy syndrome	4.34e-06	4.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	4.29e-06	4.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—epilepsy syndrome	4.27e-06	4.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	4.24e-06	4.42e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	4.23e-06	4.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCL2—epilepsy syndrome	4.18e-06	4.36e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	4.16e-06	4.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGF2—epilepsy syndrome	4.14e-06	4.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TSC2—epilepsy syndrome	4.12e-06	4.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AGT—epilepsy syndrome	4.12e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PLCB1—epilepsy syndrome	4.11e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGF2—epilepsy syndrome	4.11e-06	4.28e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	4.1e-06	4.27e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—TH—epilepsy syndrome	4.1e-06	4.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—epilepsy syndrome	4.03e-06	4.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGF2—epilepsy syndrome	4.02e-06	4.19e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	3.98e-06	4.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	3.98e-06	4.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—epilepsy syndrome	3.95e-06	4.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	3.88e-06	4.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGT—epilepsy syndrome	3.87e-06	4.03e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—RELA—epilepsy syndrome	3.84e-06	4e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—RELA—epilepsy syndrome	3.81e-06	3.97e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKCB—epilepsy syndrome	3.8e-06	3.96e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—epilepsy syndrome	3.79e-06	3.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6ST—epilepsy syndrome	3.79e-06	3.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGF2—epilepsy syndrome	3.78e-06	3.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	3.77e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MTOR—epilepsy syndrome	3.77e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	3.76e-06	3.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	3.75e-06	3.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MTOR—epilepsy syndrome	3.74e-06	3.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—RELA—epilepsy syndrome	3.73e-06	3.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MTOR—epilepsy syndrome	3.66e-06	3.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	3.62e-06	3.78e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	3.58e-06	3.73e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—RELA—epilepsy syndrome	3.51e-06	3.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—epilepsy syndrome	3.5e-06	3.65e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	3.48e-06	3.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—epilepsy syndrome	3.47e-06	3.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—epilepsy syndrome	3.47e-06	3.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—epilepsy syndrome	3.47e-06	3.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—epilepsy syndrome	3.44e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—epilepsy syndrome	3.44e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—epilepsy syndrome	3.42e-06	3.56e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	3.41e-06	3.55e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.4e-06	3.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—epilepsy syndrome	3.39e-06	3.53e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—epilepsy syndrome	3.37e-06	3.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—epilepsy syndrome	3.37e-06	3.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JUN—epilepsy syndrome	3.37e-06	3.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JUN—epilepsy syndrome	3.34e-06	3.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—epilepsy syndrome	3.28e-06	3.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JUN—epilepsy syndrome	3.27e-06	3.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—epilepsy syndrome	3.26e-06	3.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—epilepsy syndrome	3.25e-06	3.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	3.24e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	3.24e-06	3.38e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	3.24e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	3.22e-06	3.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—epilepsy syndrome	3.19e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—epilepsy syndrome	3.18e-06	3.32e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—epilepsy syndrome	3.18e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	3.17e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—epilepsy syndrome	3.16e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	3.16e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—epilepsy syndrome	3.15e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	3.14e-06	3.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	3.11e-06	3.24e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—epilepsy syndrome	3.09e-06	3.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JUN—epilepsy syndrome	3.07e-06	3.2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—epilepsy syndrome	3.06e-06	3.19e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—epilepsy syndrome	3.05e-06	3.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SRC—epilepsy syndrome	3.02e-06	3.15e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SRC—epilepsy syndrome	3e-06	3.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	2.99e-06	3.12e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—epilepsy syndrome	2.99e-06	3.12e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	2.98e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—epilepsy syndrome	2.97e-06	3.09e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—epilepsy syndrome	2.94e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SRC—epilepsy syndrome	2.93e-06	3.06e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—epilepsy syndrome	2.92e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—epilepsy syndrome	2.9e-06	3.02e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—epilepsy syndrome	2.86e-06	2.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—RELA—epilepsy syndrome	2.84e-06	2.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	2.83e-06	2.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—epilepsy syndrome	2.79e-06	2.91e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SRC—epilepsy syndrome	2.76e-06	2.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	2.72e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	2.7e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—BCHE—epilepsy syndrome	2.69e-06	2.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—epilepsy syndrome	2.68e-06	2.8e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGT—epilepsy syndrome	2.68e-06	2.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	2.66e-06	2.78e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—epilepsy syndrome	2.62e-06	2.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	2.6e-06	2.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.59e-06	2.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—epilepsy syndrome	2.57e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	2.56e-06	2.67e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	2.53e-06	2.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—TH—epilepsy syndrome	2.52e-06	2.63e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JUN—epilepsy syndrome	2.49e-06	2.6e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—epilepsy syndrome	2.42e-06	2.53e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	2.41e-06	2.51e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—epilepsy syndrome	2.35e-06	2.45e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—epilepsy syndrome	2.25e-06	2.35e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	2.24e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SRC—epilepsy syndrome	2.24e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	2.19e-06	2.28e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—epilepsy syndrome	2.18e-06	2.27e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	2.11e-06	2.2e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—epilepsy syndrome	2.08e-06	2.17e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—epilepsy syndrome	2.05e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	2.04e-06	2.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	2.02e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	2.02e-06	2.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	1.96e-06	2.04e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	1.91e-06	1.99e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—epilepsy syndrome	1.88e-06	1.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—epilepsy syndrome	1.88e-06	1.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—epilepsy syndrome	1.86e-06	1.94e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	1.85e-06	1.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—epilepsy syndrome	1.82e-06	1.9e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—epilepsy syndrome	1.8e-06	1.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	1.76e-06	1.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—epilepsy syndrome	1.71e-06	1.79e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	1.71e-06	1.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.65e-06	1.72e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—epilepsy syndrome	1.62e-06	1.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—epilepsy syndrome	1.39e-06	1.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—epilepsy syndrome	1.39e-06	1.45e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—epilepsy syndrome	1.31e-06	1.36e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—epilepsy syndrome	1.27e-06	1.32e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	1.11e-06	1.15e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	1.09e-06	1.14e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—epilepsy syndrome	9.03e-07	9.41e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—epilepsy syndrome	5.56e-07	5.8e-06	CbGpPWpGaD
